HemaCare to Chair and Present at Phacilitate Leaders World Supply Chain Panel Discussion

LOS ANGELES--(BUSINESS WIRE)-- HemaCare Corp. (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, announced today that Dominic Clarke, Ph.D., Global Head of Cell Therapy, will chair and present at Phacilitate Leaders World, one of the largest Cell and Gene Therapy conferences globally.

The meeting which has the most comprehensive cell and gene therapy agenda in the industry is to be held January 22-25, in Miami, Florida. Dr. Clarke is invited to speak at 1:30 pm EST on Wednesday, January 23, as part of the supply chain session on "Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for Clinical and Commercial Development."

With over 15 years of experience developing and enabling solutions for cell therapy and bioprocessing applications, Dr. Clarke is currently collaborating with a team of scientists in the development of HemaCare’s GMP product and services line. His presentation will discuss how critical it is to improve the stability and quality of donor starting material.

“The need for high-quality starting material is crucial to the success of cell therapies since the number of healthy cells in leukapheresis-derived material directly impacts downstream manufacturing steps and the efficacy of the final product,” said Dr. Clarke. “During the panel discussion, my colleagues and I look forward to examining common pitfalls and how best to solve starting material quality challenges in clinical and commercial cell therapy development.”

For more information about HemaCare’s participation at the show, please contact Lou Juliano at ljuliano@hemacare.com.

For more information about Phacilitate Leaders World, visit www.phacilitate-leaders-world.com.

About HemaCare

HemaCare is a global leader in the customization of human-derived biological products and services for biomedical research, drug discovery and cellular therapy process development. The company’s network of FDA-registered, GMP/GTP-compliant collection centers ensure fresh donor material is available to customers and for use within HemaCare’s isolation laboratory. Human biological material including peripheral blood, bone marrow, and cord blood is isolated into various primary cells types for fresh and frozen distribution. For 40 years, HemaCare has developed an extensive registry of repeat donors and provides human-derived primary blood cells and tissues for biomedical and drug discovery research and cell therapy clinical trials, and supports commercialization with apheresis collections, directly enabling customers to advance both autologous and allogeneic cellular therapies.



Media Contact:
Maria Thompson

Business Development Contact:
Lou Juliano


Source: HemaCare Corporation

Back to news